Return to Statistics Toolbox

Correlation analysis for Study ST003286

Nodes mapped to fold-change between 2 conditions

Select one or more experimental factors for Groups 1 and 2. The members of each group should be DIFFERENT.
Group1Experimental factorGroup2
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Monoculture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Monoculture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:A549 | Culture Type:Monoculture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Monoculture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Monoculture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:H292 | Culture Type:Monoculture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Direct Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Indirect Co-culture | Immune checkpoint inhibitor:No treatment (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Monoculture | Immune checkpoint inhibitor:Ipilimumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Monoculture | Immune checkpoint inhibitor:Nivolumab (3)
Sample source:Non-small cell lung cancer cells | Cell line:PC-9 | Culture Type:Monoculture | Immune checkpoint inhibitor:No treatment (3)
Analysis:  Combine data for all analyses?:

  logo